Project Grant R41HL174307
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- This federal Project Grant award of $313,302.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel lead delivery platform for precise cardiac conduction system pacing. The key products and services to be delivered include a 3D pre-shaped delivery catheter with features to enable physicians to monitor pacing parameters, implant depth, and cardiac conduction system capture during the implantation...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- This $397,034 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to the Massachusetts Institute of Technology (MIT) on September 1, 2025 supports the development of a Transcatheter Manufacturing Toolkit for Minimally-Invasive and Patient-Specific Device-Based Stroke Prevention. The key product being developed under this grant is a system to create fully-soft, personalized medical implants directly inside the patient's body in a...
- This federal Project Grant award of $598,636, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports the development of the EMULAATE platform by Spheric Bio Inc. The EMULAATE technology aims to address the mismatch between standard left atrial appendage occlusion (LAAO) devices and patient anatomy by enabling the assembly of personalized, soft implants directly inside the patient's body through a minimally-invasive procedure. This could...
- This $323,230 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a multi-channel radiofrequency and pulsed field energy source generator for cardiac ablation procedures. The award recipient, Sirona Medical Technologies, Inc., is developing a novel catheter device and customizable energy generator to improve the safety and precision of cardiac ablation treatments. Key product features include...
- This Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), funds the development of Heartpoint Global's IntelliSent - a minimally invasive, adjustable pulmonary flow restrictor system for pediatric and congenital heart disease patients. The $1,771,084 award supports efforts to (1) downsize the IntelliSent device to be suitable for patients from birth, including preclinical testing, (2) complete...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $293,653 to 3DT Holdings, LLC to develop a software tool for optimizing cardiac resynchronization therapy (CRT), conduction system pacing (CSP), and left ventricular endocardial pacing (LVEP) therapies. The goal is to reduce non-responder rates and improve patient identification for these treatments, especially for patients with...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $499,932 to Safebvm Corp., a small disadvantaged business located in Boston, MA, to integrate the company's SOTAIR device with capnography monitoring to standardize manual ventilation techniques and improve patient outcomes. The SOTAIR device is designed to prevent complications associated with improper manual ventilation, which can lead to costly complications...
- This Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, provides $920,176 under the Cardiovascular Diseases Research program to develop a smart aspiration catheter with fiber optic pressure sensors for mechanical thrombectomy procedures to treat acute ischemic stroke. The catheter will be designed, prototyped and validated at Worcester Polytechnic Institute to provide real-time data to interventionalists on the interaction...
PERISCOPE: A NOVEL VIDEOSCOPE AND TOOLKIT TO ENABLE FLUORO-FREE PERICARDIAL ACCESS FOR EPICARDIAL ABLATION - PROJECT SUMMARY SAFE PERICARDIAL ACCESS IS AN ESSENTIAL AND CHALLENGING FIRST STEP FOR EPICARDIAL PROCEDURES SUCH AS EPICARDIAL ABLATION. OVER 300,000 ABLATION PROCEDURES ARE PERFORMED ANNUALLY IN THE UNITED STATES ALONE, AND 20% OF PATIENTS SUFFERING FROM VENTRICULAR TACHYCARDIA WILL NEED A PERICARDIAL ACCESS PROCEDURE FOR EPICARDIAL ABLATION OF THE HEART. THE CURRENT STANDARD OF CARE FOR THESE PATIENTS IS FLUOROSCOPICALLY GUIDED PERICARDIAL ACCESS. UNFORTUNATELY, TISSUES LAYERS AND KEY CARDIAC STRUCTURES ARE NOT EASILY VISIBLE UNDER FLUOROSCOPY LEADING TO ACCIDENTAL NEEDLE STICK WITH VENTRICULAR PUNCTURE AND EXCESSIVE PERICARDIAL BLEEDING IN 10% OF CASES. IN LOW VOLUME CENTERS, COMPLICATIONS ARE EVEN MORE COMMON, AND CARDIOTHORACIC SURGEONS ARE ON-SITE TO PERFORM EMERGENCY SURGERY IF NECESSARY. THERE IS A CLEAR UNMET CLINICAL NEED FOR A DEVICE TO ENABLE SAFE, CONSISTENT, PERICARDIAL ACCESS AS AN ALTERNATIVE TO FLUOROSCOPIC GUIDANCE. THE GOAL OF THIS PHASE I STTR PROJECT IS TO DEMONSTRATE SUPERIOR PERICARDIAL ACCESS WITH RESULTING EPICARDIAL MAPPING AND ABLATION USING COLOR IMAGING AS COMPARED TO FLUOROSCOPICALLY GUIDED PROCEDURES (STANDARD OF CARE). TO ACHIEVE THIS GOAL, WE WILL COMPLETE THE FOLLOWING SPECIFIC AIMS: AIM 1: DEVELOP THE NEXT GENERATION PERISCOPE DEVICE AND DEMONSTRATE USABILITY AND COMPATIBILITY WITH FLUORO-FREE EPICARDIAL MAPPING. WE WILL 1) REDUCE PERISCOPE'S ACCESS NEEDLE TO 18G WHILE MAINTAINING HIGH IMAGE RESOLUTION IMAGE QUALITY AND 2) DEVELOP A COLOR IMAGING INTRODUCER TO VISUALIZE ABLATION CATHETERS ENTERING THE PERICARDIAL SPACE. THESE INNOVATIONS WILL ENABLE A FLUOROLESS PERICARDIAL ACCESS PROCEDURE WHICH WILL BE VALIDATED IN A 24 SUBJECT USABILITY STUDY. AIM 2: DEMONSTRATE IMPROVED PERICARDIAL ACCESS IN AN ACUTE IN VIVO STUDY. WE WILL COMPARE PERICARDIAL ACCESS WITH RESULTING EPICARDIAL MAPPING AND ABLATION USING THE FLUORO-FREE PERISCOPE TOOL TO FLUOROSCOPICALLY GUIDED PROCEDURES. WE WILL COMPARE PROCEDURE TIMES AND SAFETY AS MEASURED BY 1) NUMBER OF PERICARDIAL ACCESS ATTEMPTS, 2) SEVERITY OF COMPLICATIONS, 3) NUMBER OF HEART PERFORATIONS, AND 4) RESULTING VOLUME OF PERICARDIAL BLEEDING. THIS RESEARCH COULD HAVE A TRANSFORMATIVE IMPACT IN CHANGING CURRENT CLINICAL PRACTICE BY CONVERTING A CHALLENGING FLUOROSCOPICALLY GUIDED PROCEDURE TO A MORE INTUITIVE AND SAFE COLOR IMAGING TECHNIQUE. WHILE THIS STUDY FOCUSES ON PERICARDIAL ACCESS FOR EPICARDIAL ABLATION, THE TECHNIQUE COULD ALSO BE USED TO DELIVER EPICARDIAL PACING AND DEFIBRILLATION THERAPIES FOR INFANTS AND CHILDREN WITH CONGENITAL HEART DISEASE, AS WELL AS BENEFIT THOUSANDS OF ADULT PATIENTS WHO HAVE INDICATIONS FOR CARDIAC RESYNCHRONIZATION THERAPY BUT DO NOT ACHIEVE SUCCESSFUL IMPLANTATION DUE TO LACK OF TRANSVENOUS ACCESS OR ADEQUATE CORONARY SINUS VENOUS TRIBUTARIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $295.9k | 4/15/24 |